Nicole Lamanna is an Oncology physician affiliated with NewYork–Presbyterian Hospital. OpenAlex indexes 389 publications with 8,797 citations (h-index 39); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
622 W 168th St
New York, NY 100323720
Telephone
646-317-5077Registry record last updated 22 Nov 2017.
Clinical trials
- Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
Sponsor: Memorial Sloan Kettering Cancer Center
- Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma
Sponsor: Memorial Sloan Kettering Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
18 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- BeOne Medicines USA, Inc.Program year202511 payments
- AstraZeneca Pharmaceuticals LPProgram year20252 payments
- Genmab U.S., Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
65.4%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor39.6%Valacyclovir100%Part D≥21 patientsPenicillins with extended spectrum10.4%Amoxicillin-Clavulanate Potass100%Part D≥17 patients+ 2 more classes in this area
Blood & clotting
14.3%Salt solutions7.1%Sodium Chloride100%Part D<11 patientsFactor Xa inhibitor7.1%Eliquis100%Part D<11 patientsRespiratory
7.1%Corticosteroid7.1%Fluticasone Propionate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
New England Journal of Medicine
2023 - Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma
Journal of Clinical Oncology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Lawrence Honig, MD, PhD
NewYork–Presbyterian Hospital
Nasser Altorki, MD
NewYork–Presbyterian Hospital
Michael Niederman, MD
NewYork–Presbyterian Hospital
Shunichi Homma, MD
NewYork–Presbyterian Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”